中国血液净化

›› 2011, Vol. 10 ›› Issue (10): 535-537.doi: R318.16 R512.6

• 临床研究 • 上一篇    下一篇

透析间期抗凝对血液透析长期留置管生存寿命的影响

龙春姣 李远明 孙永超 王露芳 彭 兰 谢辉乐 伍 锟

  

  1. 中南大学湘雅三医院血液透析中心
  • 收稿日期:2011-07-05 修回日期:1900-01-01 出版日期:2011-10-12 发布日期:2011-10-12
  • 通讯作者: 伍锟

The influence of systemic anticoagulation with warfarin between dialysis sessions on survival in hemodialysis patients with long-term indwelling catheters

LONG Chun-jiao, LI Yuan-ming, SUN Yong-chao, WANG Lu-fang, PENG Lan, XIE Hui-le, WU Kun   

  1. Blood Hemodialysis Center, the Third Xiangya Hospital, Central South University, Changsha 410013, China
  • Received:2011-07-05 Revised:1900-01-01 Online:2011-10-12 Published:2011-10-12

RichHTML

3

PDF

278

摘要：

目的 血液透析长期导管是透析患者重要的血管通路之一，然而其功能障碍和感染仍然比较频繁。透析间期华法林抗凝对血液透析导管的通畅性的维持可能会有益。本研究前瞻性地比较了透析间期口服华法林抗凝和不服抗凝剂两种方法的长期结果。 方法 从2006年1月至2011年1月，309例Permcath隧道导管植入慢性血液透析患者颈内静脉，144例使用华法林抗凝和165例不使用抗凝剂。前瞻性随访患者导管感染和通畅率。 结果 抗凝治疗组的平均导管存活(无功能障碍)时间比对照组明显延长(31.8±0.9月比 22.0±1.2月，P＜0.01)，3年通畅率也明显增高(82.6%比51.5%，P =0.003)。2组导管感染率明显降低(5.6% 比14.5%，P＜0.05)。 结论 透析间期口服适量的华法林能明显延透析患者长期导管的使用寿命，并减少患者的导管血栓形成率和感染率。

关键词: 血液透析, 长期导管, 透析间期抗凝, 血栓形成, 感染率, 生存率

Abstract:

Objective Long-term indwelling catheter is an alternative approach for vascular access in hemodialysis patients. However, complications such as thromboses and infections often lead to catheter dysfunction. To investigate the effect of anticoagulation on catheter patency, we used warfarin between dialysis sessions in hemodialysis patients with tunneled, cuffed and indwelling catheters in right internal jugular vein. Method In a cohort of 309 hemodialysis patients implanted with cuffed dual-lumen catheters in right jugular vein as vascular access, 144 patients took adjusted doses of warfarin between dialysis sessions, and the remaining 165 cases without anticoagulation medication were served as controls. Catheter patency and infection rate were monitored. The study end point arrived when their blood flow during a dialysis session became <200ml/min, they had refractory catheter infection, or their observation period reached to 36 months. Results The average survival period of catheter was significantly longer in anticoagulant group than in control group (31.8±0.9 months vs. 22.0±1.2 months, P＜0.01). Moreover, patients in anticoagulant group had a higher 3-year patency rate (82.6% vs 51.5%, P = 0.003) and a lower catheter infection rate (5.6% vs 14.5%, P＜0.05). Conclusion Warfarin is effective in extending catheter patency period and lowering local infection rate.

Key words: Long-term catheter, Anticoagulation, Thrombosis, Infection, Patency rate